Comprehensive Study Guide to Intellectual Property Law and Patent Practice

Fundamentals of the Intellectual Property System

• The intellectual property (IP) legal framework encompasses distinct branches: copyright, designs, patents, trademarks, trade secrets, and unfair competition.

• Historical Evolution of IP Concepts:

  • The Venetian Patent Statute of 1474: One of the earliest codified patent systems, granting a 10-year term of exclusivity to inventors of new and ingenious contrivances in the city of Venice to attract skilled artisans.

  • Gutenberg's Printing Press (15th Century): Shifted focus onto the "original" work. Before mechanical printing, hand-copied manuscripts by monks and nuns made little distinction between original and copy. Mass printing made the master original economically vital.

  • Josef Kohler's Immaterial Goods Theory (Late 19th Century): Kohler, considered the father of the European IP system, conceptualized IP as protection over intangible/immaterial goods (Immaterialgüter). Unlike physical property, immaterial goods can be shared and enjoyed concurrently by multiple people without physical depletion.

  • Anglo-American vs. Continental Approach: Post-WWII shifts brought the Anglo-American concept of property ("land and no trespassing") into dominant international IP discourse, moving away from Kohler's philosophical model toward a purely economic, market-dominance orientation.

• Paradigm Shifts in the IP Landscape:

  • From Exceptions to the Norm: IP rights originally functioned as narrow, exceptional monopolies in a system committed to free trade. Today, the market is flooded with exclusive rights, making proprietary control the norm rather than the exception.

  • Threshold Adjustments: Increased density of exclusive rights forces adjustments in protection thresholds (e.g., higher originality standards in copyright post-Cofemel and Mio cases) to preserve competitive space for third parties.

  • Harmonization to Standardization: International IP transitioned from consensus-building harmonization under WIPO toward strict economic standardization enforced by WTO trade sanctions under the TRIPS Agreement.

  • From Qualified Objects to Investment Safeguards: Modern IP increasingly protects capital investment and commercial effort rather than purely qualified human intellectual creation (e.g., the sui generis Database Right under Directive 96/9/EC).

• The Balancing Role of Intellectual Property Law:

  • IP law operates as a balancing lever (read-out balance) between private exclusive rights and public domain/third-party freedom of competition.

  • Key constitutional benchmarks under the Charter of Fundamental Rights of the European Union (CFR):

  • Article 11: Freedom of expression and information (protecting parodies, public debate, and transformative uses).

  • Article 16: Freedom to conduct a business.

  • Article 17(2): Protection of intellectual property.

  • Article 1 & 35: Inviolability of human dignity, right to life, and a high level of human health protection.

Legal and Institutional Frameworks for Patents

• International Frameworks:

  • Paris Convention for the Protection of Industrial Property (1883):

  • Establishes the principle of territoriality (patent rights are independent in each contracting state).

  • Establishes national treatment (foreign nationals receive equal treatment to domestic citizens).

  • Grants a 12-month Convention Priority period ($t=0$ to $t=12$ months) from the first filing date ($F_0$) in a member state for subsequent filings ($F_1, F_2$) in other member states.

• Patent Cooperation Treaty (PCT, 1970):

  • Administered by WIPO; allows a single unified international patent application.

  • Does not grant an "international patent" (which does not exist); provides a centralized prior art search report and preliminary examination, delaying national/regional phase entry decisions until $30$–$31$ months from the priority date.

• TRIPS Agreement (1994):

  • Annex 1C of the WTO Agreement; binds all WTO members to baseline standards (e.g., 20-year patent term from filing date under Article 33).

  • Integrated into the WTO dispute settlement mechanism, permitting cross-sectoral trade retaliation against non-compliant member states.

  • European Framework:

• European Patent Convention (EPC 1973 / EPC 2000):

  • A non-EU regional treaty establishing the European Patent Organisation (EPOrg).

  • Establishes a single, centralized application and examination procedure at the European Patent Office (EPO).

  • Once granted, a "classic" European patent becomes a bundle of national patents in the designated member states ($39$ contracting states as of 2026, including all $27$ EU member states plus non-EU states such as the UK, Switzerland, Norway, and Turkey).

• Institutional Architecture of EPOrg:

  • Administrative Council: Legislative/supervisory body consisting of delegates from member states; competent to amend the Implementing Regulations (Article 33(1)(c) EPC).

  • European Patent Office (EPO): Executive body responsible for examining applications and granting European patents.

  • Boards of Appeal / Enlarged Board of Appeal (EBA): Independent judicial body within the EPOrg structure responsible for final judicial review of EPO decisions.

• EU Legislation and CJEU Jurisdiction:

  • EU Directives/Regulations: Biotech Directive 98/44/EC, Enforcement Directive 2004/48/EC, SPC Regulation (EC) No 469/2009, Brussels I Regulation (EU) No 1215/2012.

  • Court of Justice of the European Union (CJEU): Possesses exclusive interpretative supremacy over EU law (Article 267 TFEU), but has a limited mandate in patent law limited to EU directives/regulations (e.g., Brüstle v. Greenpeace, C-34/10).

  • Unitary Patent (UP) and Unified Patent Court (UPC):

• Established under EU Enhanced Cooperation (Regulations (EU) No 1257/2012 & 1260/2012) and the international Agreement on a Unified Patent Court (UPCA).

• Unitary Patent (UP): A single European patent granted by the EPO that receives unitary effect across participating EU member states ($18$ states ratified as of 2026 out of $24$ signatories and $25$ participating states).

• Unified Patent Court (UPC) Structure:

- **Court of First Instance**:
  - *Central Division*: Headquartered in Paris (with sections in Munich and Milan).
  - *Local Divisions*: Located in individual member states (e.g., Germany has 4: Düsseldorf, Munich, Hamburg, Mannheim; Austria, Belgium, Denmark, Finland, France, Italy, Netherlands, Portugal, Slovenia).
  - *Regional Division*: Nordic-Baltic Regional Division located in Stockholm (covering Sweden, Estonia, Latvia, Lithuania).
- **Court of Appeal**: Located in Luxembourg (panel of 3 legally qualified judges and 2 technically qualified judges).
- **Centres for Mediation and Arbitration**: Located in Lisbon and Ljubljana.

• Transitional Opt-Out Regime:

  • During a 7-year transition period (extendable to 14 years), proprietors of "classic" European patents can formally opt out of the UPC's exclusive jurisdiction, retaining enforcement/revocation before national courts.

  • If a national court action has already commenced regarding a classic EP, the opt-out cannot be withdrawn ("pinned").

  • Swedish Legal Framework:

• Swedish Patent Act (Patentlagen 2024:945): Governs national patent rights and reflects EPC/UPC substantive standards.

• Swedish Court System:

- Two-tier specialized court system established in 2016:
  - **Patent and Market Court (*Patent- och marknadsdomstolen*)**: First instance at Stockholm District Court. Panels consist of 1–3 legal judges and 1–3 technical judges.
  - **Patent and Market Court of Appeal (*Patent- och marknadsöverdomstolen*)**: Second instance at Svea Court of Appeal. Panel of 3–4 legal judges and 1–3 technical judges. Requires leave to appeal (*prövningstillstånd*).
  - **Supreme Court (*Högsta domstolen*)**: Hears appeals only on exceptional legal issues of precedential value when leave to appeal is granted by both the Court of Appeal and the Supreme Court.

Substantive Requirements for Patentability

• To obtain a patent under Article 52(1) EPC, a technical solution must satisfy four core substantive requirements:

  1. Must be an invention having a technical character.

  2. Must be novel.

  3. Must involve an inventive step.

  4. Must be susceptible of industrial application.

• Definition of Invention & Technical Character:

  • The EPC contains no positive legal definition of an "invention", maintaining flexibility for emerging technologies.

  • The core requirement is technical character: the subject matter must define a concrete technical solution to a technical problem expressed through at least one technical feature.

• Novelty (Articles 54(1), 54(2), 54(3) EPC):

  • Absolute Global Novelty Standard: An invention is novel if it does not form part of the state of the art.

  • State of the Art (Article 54(2) EPC): Everything made available to the public anywhere in the world by means of a written or oral description, by use, or in any other way, before the filing date or valid priority date.

  • Prior Applications (Article 54(3) EPC): European patent applications filed earlier but published on or after the filing/priority date of the application under examination form part of the state of the art for novelty purposes only (not for inventive step).

  • Single-Document Rule: Novelty destruction requires that all technical features of a claimed invention be directly, unambiguously, and explicitly or implicitly derivable from a single prior art document/source.

  • Non-Prejudicial Disclosures (Article 55 EPC): A 6-month grace period prior to the filing date applies only if the disclosure resulted from an evident abuse in relation to the applicant or display at an official international exhibition.

• Inventive Step (Article 56 EPC):

  • An invention involves an inventive step if, having regard to the state of the art, it is not obvious to a person skilled in the art.

  • Article 54(3) documents are excluded from the state of the art when assessing inventive step.

  • The Problem-Solution Approach (Mandatory EPO methodology):

  1. Identify the Closest Prior Art: Select the single prior art document/source in the same or neighboring technical field that serves as the most promising starting point (most similar structure/purpose).

  2. Determine the Differing Features and Technical Effect: Compare the claim with the closest prior art to identify structural/functional differences and establish the technical effect resulting from those differences.

  3. Formulate the Objective Technical Problem: Define the technical problem to be solved without using hindsight or embedding aspects of the solution into the problem formulation.

  4. The "Could-Would" Test: Assess whether the person skilled in the art, faced with the objective technical problem, would (not merely could) have modified the closest prior art by combining it with another prior art teaching or common general knowledge to arrive at the claimed invention.

  • Secondary Indicators of Inventive Step:

  • Long-felt technical need solved by the invention.

  • Overcoming a long-standing technical prejudice.

  • Unexpected technical/bonus effect (Bonus-Effekt).

  • Commercial success (given limited weight; must be proved to stem directly from the technical features, not marketing).

• The Person Skilled in the Art:

  • A hypothetical legal construct: an average practitioner/engineer (or team of experts in multidisciplinary fields) in the relevant technical field.

  • Possesses the complete common general knowledge of the field (textbooks, standard references) and has access to all prior art in neighboring/abstract fields.

  • Capable of routine experimentation and work, but lacks any creative or inventive capacity.

• Industrial Application (Article 57 EPC):

  • An invention is susceptible of industrial application if it can be made or used in any kind of industry, including agriculture.

  • Excludes perpetuum mobile devices, processes violating established physical laws (e.g., cold fusion), or completely non-repeatable/chance phenomena.

• Sufficiency of Disclosure & Formal Requirements:

  • Sufficiency of Disclosure (Article 83 EPC): The application must disclose the invention in a manner sufficiently clear and complete for it to be carried out by a person skilled in the art without undue burden.

  • Clarity and Conciseness of Claims (Article 84 EPC): Claims must define the matter for which protection is sought, be clear, concise, and supported by the description.

  • Reproducibility: The technical results must be repeatable reliably across the entire scope claimed.

Statutory Exclusions and Exceptions from Patentability

• Non-Inventions under Article 52(2) & 52(3) EPC ("As Such" Exclusion):

  • Article 52(2) lists items not regarded as inventions; Article 52(3) restricts this exclusion strictly to subject matter claimed "as such".

  • The Comviq Approach (T 641/00 / T 258/03 Hitachi):

  • A claim containing at least one physical/technical feature (e.g., a computer, a server, or pen and paper) possesses technical character and is not excluded under Article 52(2) EPC.

  • Non-technical features are not removed at the eligibility stage. Instead, the assessment moves to inventive step (Article 56 EPC).

  • Non-technical features that do not interact with technical features to produce a technical effect are ignored in the inventive step assessment, or are given to the skilled person as a non-technical business constraint in the problem formulation.

• Categorical Analysis of Non-Inventions:

  • Discoveries, Scientific Theories, Mathematical Methods:

  • Purely abstract mathematical algorithms or scientific theories lack technical character.

  • Exception: Patentable when applied in a specific technical context (e.g., Fast Fourier Transform used specifically for digital audio signal filtering) or tailored to a specific technical hardware architecture (e.g., an algorithm optimized for 64-bit CPU register structures).

  • Aesthetic Creations:

  • Purely aesthetic features (e.g., a decorative pattern on a tire) are excluded.

  • Exception: Functional aspects of a design (e.g., tire tread patterns designed to channel water to prevent hydroplaning) are technical and patentable.

  • Schemes, Rules, and Methods for Mental Acts, Games, or Business:

  • Mental acts (performed purely in the human mind) and business methods (e.g., single-account bookkeeping, financial trading schemes) are non-technical.

  • Game rules as such (e.g., rolling dice to move pieces) are excluded, but concrete technical hardware or software engines enforcing rules efficiently (e.g., pseudo-random number generators or 3D rendering engines) are patentable.

  • Computer Programs & Computer-Implemented Inventions (CIIs):

  • Source code as an artistic expression is protected by copyright.

  • Software functionality / algorithms are patentable as CIIs if the execution of the software on a computer produces a "further technical effect" going beyond the normal physical interactions between software and hardware (T 1173/97, G 3/08).

- Examples of further technical effects: ABS braking control, video stream compression algorithms, data encryption, hardware memory management.

• Artificial Intelligence (AI) and Machine Learning:

  • AI models, neural networks, and LLMs are classified as mathematical/statistical methods.

  • Patentable subject matter includes specific technical training setups, neural network hardware architectures (e.g., transformer self-attention mechanisms), or technical applications (e.g., medical image classification for tumor detection).

• Simulations (G 1/19 Pedestrian Simulation):

  • Computer-implemented numerical simulations are patentable if they solve a technical problem in a specified technical context (e.g., simulating building design or pedestrian flow for structural layout) or produce a further technical effect (e.g., optimizing computer resource allocation during execution).

• Presentations of Information & User Interfaces:

  • Cognitive/linguistic presentation of information (e.g., displaying text in Spanish vs English) is non-technical.

  • Graphical User Interfaces (GUIs) are technical if the presentation dynamically reflects the internal technical state of the machine and aids the user in performing a technical control task.

  • Exceptions from Patentability under Article 53 EPC:

• Ordre Public and Morality (Article 53(a) EPC & Rule 28 EPC):

  • Excludes inventions whose commercial exploitation violates public order or morality (e.g., letter bombs, torture devices).

  • Biotechnology Exclusions (Biotech Directive 98/44/EC & Rule 28 EPC):

    • Processes for cloning human beings.

    • Processes for modifying the germline genetic identity of human beings.

    • Uses of human embryos for industrial or commercial purposes (Brüstle v. Greenpeace, C-34/10; G 2/06 WARF).

    • Processes for modifying the genetic identity of animals likely to cause them suffering without substantial medical benefit.

• Plant and Animal Varieties & Essentially Biological Processes (Article 53(b) EPC):

  • Plant varieties (protected separately under sui generis Plant Variety Rights) and animal varieties are unpatentable.

  • Essentially biological processes (consisting entirely of natural phenomena such as crossing and selection) are unpatentable.

  • G 3/19 (Pepper): Dynamic interpretation of Article 53(b) EPC established that product claims or product-by-process claims directed to plants or plant material exclusively obtained by essentially biological processes are excluded from patentability (reversing G 2/12 Tomatoes II / Broccoli II for applications filed/granted on or after 1 July 2017).

• Medical Methods (Article 53(c) EPC):

  • Excludes methods for treatment of the human or animal body by surgery or therapy, and diagnostic methods practiced on the human or animal body.

  • Rationale: Protects medical doctors from patent infringement liability when treating patients.

  • Products and Compositions: Medical devices, pharmaceuticals, and surgical tools remain patentable.

  • First and Second Medical Indications: First medical use of a known substance ($X$ for use as a medicament) and second/further medical uses ($X$ for use in treating disease $Y$) are patentable under Article 54(4) and 54(5) EPC.

Patent Drafting, Structure, and Application Procedure

• Anatomy of a Patent Document:

• Bibliographic Data: Application/grant number, filing date, priority date, applicant name, inventor name, IPC/CPC classification.

• Abstract: Concise summary (approx. 150 words) serving purely as a technical search aid.

• Description:

  • Field of the invention and technical background.

  • Summary of prior art and its drawbacks.

  • Technical problem and its solution.

  • Detailed description of at least one embodiment and worked examples.

• Claims: Define the legal scope of the monopoly.

  • Independent Claims: Standalone claims containing all essential features of the broadest version of the invention.

  • Dependent Claims: Refer back to an independent claim, incorporating all its features plus additional limiting features; serve as pre-drafted fallback positions during examination or litigation.

• Drawings: Schematic diagrams illustrating the description and claims.

  • Claim Drafting Strategy:

• Feature Minimization: Independent claims should contain only the minimal necessary features required to overcome prior art. Adding unneeded features narrows protection and allows competitors to design around the patent.

• All-Elements Rule: To prove direct infringement, the accused product/process must embody every single feature listed in the independent claim.

  • EPO Grant Procedure Timeline:

• Filing ($t = 0$): Application submitted; formalities examination.

• Priority Window ($t = 0$ to $t = 12$ months): Filing in additional countries claiming Paris Convention priority.

• Publication ($t = 18$ months): Application and European Search Report published; file becomes open to public inspection.

• Substantive Examination: Examiner issues Office Actions; applicant submits claim amendments and arguments.

• Grant ($t = 4$–$5$ years): Decision to grant issued; mention of grant published in European Patent Bulletin.

• Post-Grant Phase:

  • Opposition Window: 9-month time limit from grant publication for third parties to file an opposition before the EPO.

  • Unitary Patent Request: 1-month time limit from grant publication to request Unitary Effect.

  • National Validation: 3-month time limit from grant publication for validating classic EPs in non-UP member states.

Patent Infringement, Scope of Protection, and Enforcement

• Determining the Scope of Protection:

  • Article 69 EPC & Protocol on Interpretation:

  • Scope is determined by the claims, with description and drawings used for interpretation.

  • Mandates a middle ground between strict literal wording (UK traditional approach) and broad speculative guidelines (German traditional approach) to combine fair protection for the patentee with reasonable legal certainty for third parties.

  • Feature Analysis:

• The Doctrine of Equivalents:

  • Extends protection beyond literal wording to variants that perform substantially the same function in substantially the same way to achieve the same result.

  • UK Purposive Construction (Catnic v. Hill & Smith; Actavis v. ICOS):

- In *Catnic*, a lintel backplate inclined at $6^\text{o}$–$8^\text{o}$ from vertical was held to infringe a claim specifying a rear member "extending vertically", as exact verticality was not an essential requirement to a person skilled in the art.

• Swedish 4-Step Criteria for Equivalence (PMÖ 744-16):

  1. The inventive concept is utilized entirely by the alleged infringing product.

  2. Achieves the same technical result despite structural differences.

  3. The differences are obvious (närliggande) to a person skilled in the art.

  4. The solution leads to a result that substitutes the patent-protected solution.

• Factors Hindering Equivalence:

  • Narrow design-around nature of the underlying invention.

  • Prosecution History Estoppel: Deliberate narrowing of claims during prosecution to overcome prior art prevents re-expanding claims via equivalence during litigation.

  • Acts of Infringement:

• Direct Infringement (Article 25 UPCA / Swedish Patent Act Ch. 5 § 1):

  • Product Patents: Making, offering, placing on the market, using, importing, or storing the product.

  • Process Patents: Using or offering the process.

  • Indirect Product Protection: Offering, placing on the market, using, importing, or storing a product obtained directly by a patented process.

• Indirect Infringement (Article 26 UPCA):

  • Supplying or offering to supply an unauthorized third party with means relating to an essential element of the invention for putting it into effect, when the third party knows (or ought to know) that the means are suitable and intended for that purpose.

• Imminent / Preparatory Infringement:

- In *Boehringer Ingelheim v. Zentiva* (UPC Court of Appeal, 2024), obtaining pricing/reimbursement approval (PEP) and marketing authorization (MA) prior to patent expiration constituted imminent infringement, empowering courts to issue preliminary injunctions.

• Complicit Infringement:

  • Aiding, abetting, or encouraging patent infringement under Chapter 23 of the Swedish Criminal Code.

  • Exceptions and Defences to Exclusive Rights:

• Private and Non-Commercial Use: Private acts performed for non-commercial purposes.

• Experimental Use & Bolar Exemption:

  • Experimental acts relating to the subject matter of the patented invention.

  • Bolar Exemption: Conducting necessary studies, tests, and trials to obtain regulatory marketing authorization for generic pharmaceuticals.

• Exhaustion of Rights: Rights are exhausted once a patented product is placed on the market in the EEA by the patentee or with their express consent.

• Prior User Rights: Any person who in good faith used or made serious preparations to use an invention prior to the priority filing date retains a personal, non-transferable license to continue use within their business.

Patent Litigation Procedure and Strategy

• Pre-Litigation Strategy:

• Assembling multidisciplinary teams (outside legal counsel, in-house leaders, technical experts).

• Budgeting: Patent litigation is capital-intensive (€500,000 to €3,000,000+ in UPC/national courts).

• Cease and Desist Letters: Formally notify the infringer to establish objective knowledge/intent.

  • Securing Evidence:

• Swedish Infringement Investigation (Saisie-Contrefaçon counterpart):

  • Court-ordered ex parte inspection of premises by bailiffs to copy digital/physical evidence.

  • Requires showing probable cause and posting mandatory financial security.

  • Main summons application must be submitted within $30$ days of receiving the bailiff report.

• Article 60 UPCA: Orders to preserve evidence and inspect premises across UPC member states.

• Production of documents and court orders to provide information.

  • Preliminary Injunctions (PIs):

• Procedural Requirements: Probable cause of infringement, urgency, balance of convenience, and mandatory security.

• Presumption of Validity:

  • Granted patents carry a strong presumption of validity (Phoenix case C-44/21; Fingolimod saga PMÖ 1644-23 / PMÖ 7680-23).

  • Summary PI proceedings generally do not re-examine substantive validity unless clear, obvious errors in EPO prosecution are demonstrated.

  • Invalidity Counterclaims & Revocation Actions:

• Swedish System: Infringement and invalidity counterclaims are joined and tried together in the same proceeding before the Patent and Market Court (non-bifurcated).

• German System: Bifurcated system where infringement is tried in civil district courts while revocation is tried separately before the Federal Patent Court (Bundespatentgericht).

• UPC System: Local divisions can hear both or exercise discretion to bifurcate and refer the revocation counterclaim to the Central Division.

  • Litigation Costs and Forum Comparison:

• UPC Court Fees: Fixed fee of €11,000 for infringement or declaration of non-infringement; €20,000 for revocation. Value-based fees added for cases valued over €500,000 (up to €325,000 for cases > €50,000,000).

Specialized IP Topics: Pharmaceuticals, Trademarks, and Trade Secrets

• Pharmaceutical Patent Strategy & Lifecycle Management:

  • Evergreening: Obtaining secondary patents on incremental modifications (second medical uses, novel dosage forms, formulations, delivery devices) to extend market exclusivity beyond the 20-year term of the primary compound patent.

  • Supplementary Protection Certificates (SPCs):

  • Regulated under Regulation (EC) No 469/2009; compensates for effective patent term lost during regulatory clinical trials and marketing authorization delays.

  • Extends protection for up to $5$ additional years (plus an extra $6$ months if pediatric testing requirements under Regulation (EC) No 1901/2006 are fulfilled).

  • Max effective patent protection capped at $15$ years from the date of first EU Marketing Authorization.

  • FRAND Licensing for Medical Tech: Proposals to adapt Fair, Reasonable, and Non-Discriminatory (FRAND) licensing frameworks to essential health technologies to prevent anti-competitive refusals to license during public health emergencies.

• Trade Secrets vs. Patents:

  • Regulated under EU Trade Secrets Directive (EU) 2016/943 and national implementations (e.g., Swedish Trade Secrets Act).

  • Advantages: Unlimited duration (no 20-year expiration), no registration costs, no public disclosure required.

  • Risks: No protection against independent discovery or lawful reverse engineering; vulnerable to employee mobility.

• Genuine Use of Trademarks:

  • 5-Year Grace Period (Article 18 EUTMR): A registered EU trademark must be put to genuine use within 5 years of registration.

  • Revocation for Non-Use (Article 58 EUTMR): Failure to prove genuine use results in revocation erga omnes upon application or counterclaim.

  • Non-Use Defence (Article 47 & 127(3) EUTMR): A defendant in infringement or opposition proceedings can request the proprietor to provide proof of genuine use during the preceding 5 years.

  • Standards for Genuine Use (Ansul, Silberquelle, Leno Merken, ACTIC):

  • Must be used as a true indicator of commercial origin to create or maintain a market for the goods/services.

  • Token use (solely to preserve registration) and purely internal use do not qualify.

  • Promotional giveaways (Silberquelle) do not constitute genuine use for the giveaway item unless it supports the market for the core registered goods.

  • Territorial scope (Leno Merken): Use in a single member state may be sufficient depending on the nature of the market.